Does conversion surgery improve survival rates for patients with cT4 Esophageal Cancer?
cT4 esophageal cancer is a locally advanced tumor that has spread to nearby structures, making it difficult to remove with surgery alone. Standard treatment is definitive chemoradiotherapy (dCRT), but survival outcomes are poor. Conversion surgery (CS) — surgery performed after initial chemotherapy or chemoradiotherapy to shrink the tumor — has emerged as a potential way to improve survival. Research shows that CS can significantly increase long-term survival rates compared to dCRT alone, though it is not suitable for every patient.
What the research says
A large systematic review and meta-analysis of 17 studies involving 3,721 patients with cT4 esophageal cancer found that conversion surgery after induction therapy was associated with significantly better survival than definitive therapy alone 27. At 1 year, survival was 73.6% with CS versus 49.6% with definitive therapy; at 3 years, 37.0% versus 18.4%; and at 5 years, 26.5% versus 11.6% 27. Even for patients with the most advanced cT4b disease (tumors invading nearby organs), a subgroup analysis of 341 patients showed a significant survival advantage with CS 27.
Other studies support these findings. A multi-institutional study of 66 patients with advanced esophageal cancer and distant metastases who underwent induction therapy followed by CS reported a 5-year overall survival of 24.4% and an R0 resection rate (complete removal of visible tumor) of 92% 8. Another study of 55 patients with locally advanced unresectable esophageal cancer who received induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) found that 36 went on to CS, with a 5-year survival rate of 54% and an R0 resection rate of 81% 9.
It is important to note that conversion surgery carries risks. In the multi-institutional study, the postoperative complication rate was 47%, but in-hospital mortality was low at 1% 8. The DCF study reported no serious postoperative complications 9. Patient selection is key — those who respond well to induction therapy tend to have better outcomes 9.
What to ask your doctor
- Based on my specific tumor stage and location, am I a candidate for conversion surgery?
- What induction therapy (chemotherapy or chemoradiotherapy) would be recommended before considering surgery?
- What are the chances of achieving R0 resection (complete tumor removal) with conversion surgery in my case?
- What are the potential risks and complications of conversion surgery, and how does my overall health affect those risks?
- How does the expected survival benefit of conversion surgery compare to continuing with definitive chemoradiotherapy alone?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.